NON-SMALL CELL CARCINOMA
Clinical trials for NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to boost lung cancer treatment
Disease control OngoingThis early-phase trial tests whether adding the experimental drug binimetinib to the immunotherapy pembrolizumab (Keytruda) helps people with advanced non-small cell lung cancer. The study includes 40 participants whose tumors have high PD-L1 levels. Researchers are looking at sa…
Matched conditions: NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Triple drug cocktail targets tough lung cancer
Disease control OngoingThis pilot study tests a combination of three drugs—zimberelimab, domvanalimab, and etrumadenant—in 30 adults with advanced non-small cell lung cancer who have already been treated with immunotherapy. The goal is to see if the triple therapy is safe and can shrink tumors. The stu…
Matched conditions: NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Custom immune cells take on multiple cancers in early trial
Disease control OngoingThis early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…
Matched conditions: NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo therapy aims to outsmart tough lung cancer mutations
Disease control OngoingThis phase 3 trial compares the standard drug osimertinib alone versus osimertinib combined with two chemotherapy drugs (carboplatin and pemetrexed) as a first treatment for people with advanced non-squamous lung cancer that has both EGFR and TP53 mutations. The study involves 29…
Matched conditions: NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New blood test could spare thousands from unnecessary lung surgery
Diagnosis OngoingThis study is testing whether a blood test called Nodify XL2 can help doctors decide how to manage lung nodules that have a low to moderate chance of being cancer. About 2,000 adults with solid lung nodules between 8 and 30 mm are taking part. The goal is to see if using the test…
Matched conditions: NON-SMALL CELL CARCINOMA
Sponsor: Biodesix, Inc. • Aim: Diagnosis
Last updated Jun 26, 2026 18:51 UTC